European prize for mobile vaccination units The Netherlands’ mobile vaccination units (prikbussen) have been selected as a best-practice method for the European project ‘Overcoming Obstacles to Vaccination’.
Self-sampling device to be sent automatically, making it easier to take part in cervical cancer screening From the first week of July, every woman turning 30 will receive a self-sampling device with their invitation for cervical cancer screening. Participants can use this device to collect their own vaginal material.
Concerns over falling vaccination coverage within National Immunisation Programme The percentage of children vaccinated within the National Immunisation Programme (NIP) has fallen for the second year in a row, according to the 2022 report ‘Vaccination Coverage and Annual Report of the Dutch National Immunisation Programme'. RIVM is concerned about this decline.
Safe recycling of textiles possible, but still in its infancy Textiles are produced using chemicals. Although many hazardous chemicals may no longer be used in textile production, they may still be present in donations of old clothing. RIVM has conducted a study into the safety of recycled textiles.
No new SARS-CoV-2 variants discovered in wastewater on aircraft from China Wastewater on aircraft from China has not been found to contain any new variants of the coronavirus SARS-CoV-2 so far. These findings are from several tests performed by RIVM. However, the wastewater was found to contain coronavirus particles.
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.